表紙
市場調査レポート

ペプチドによる癌治療:世界の市場およびパイプラインの分析

Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014

発行 PNS Pharma 商品コード 311225
出版日 ページ情報 英文 556 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
ペプチドによる癌治療:世界の市場およびパイプラインの分析 Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
出版日: 2014年08月01日 ページ情報: 英文 556 Pages
概要

癌の発生を抑制あるいは癌を根絶するための従来の方法は、癌の治療において限られた成果しかあげていません。これらの方法は特異性が低く、安全性に乏しく、副作用が多くあるため、研究者はより良いソリューションを模索しています。その中で、従来の手法の欠点を持たずに効果的で実行可能な治療に利用できるとして、ペプチドが注目されています。

当レポートでは、ペプチドによる癌治療の市場について調査し、ペプチドによる癌治療のメカニズム、ペプチド癌治療薬の臨床パイプライン(フェーズ・適応症・企業・国別)、上市済み製品に関する考察、市場規模の推移と予測、市場影響因子の分析、主要企業プロファイルなどをまとめています。

第1章 ペプチドによる癌治療:イントロダクション

第2章 ペプチドによる癌治療のメカニズム

第3章 ペプチドによる癌治療の市場:展望

  • 市場概要
  • 癌ペプチドの臨床パイプライン:概要

第4章 ペプチドによる癌治療の市場:力学

  • 好ましい成長パラメーター
  • 解消すべき主要課題

第5章 ペプチドによる癌治療の市場:将来の成長の見通し

第6章 ペプチドによる癌治療薬の臨床パイプライン:フェーズ・適応症・企業・国別

  • 調査
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第7章 上市済みペプチド癌治療薬の考察:適応症・国・企業別

第8章 中止・休止中のペプチド癌治療薬臨床試験:フェーズ・適応症・企業・国別

  • 進展報告なし
  • 中止
  • 撤退
  • 延期

第9章 競合環境

  • AngioChem
  • Antigen Express
  • Amgen
  • GlaxoSmithKline
  • Galena Biopharma
  • Ipsen
  • Merck & Co
  • PeptiDream
  • Roche
  • Sanofi
目次

The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market.

The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects.

Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Brain is a very sensitive organ, to protect itself from unwanted substances it has developed blood brain barrier. It very difficult to breach, here conventional cancer therapeutics faces a sever challenge. On the other hand, peptide cancer therapeutics is able to overcome this barrier. Markets for these medicines have a huge potential and many medicines are under various phases of clinical trials

Peptide cancer therapies hold a promising future for the treatment of cancer. Various clinical trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional cancer therapy. In some studies, it has been found that combinatorial therapies will be more effective than individual methods. In combinatorial therapy, both conventional and peptide based cancer therapeutics are used for the treatment.

"Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" Report Highlight:

  • Mechanism & Market Overview of Peptide Cancer Therapeutics
  • Clinical Pipeline by Analysis Phase, Indication, Company & Country
  • Peptide Cancer Drugs in Pipeline: 183 Drugs
  • Marketed Peptide Cancer Drugs: 20 Drugs
  • Majority Drugs in Preclinical Phase: 75 Drugs
  • Suspended & Discontinued Peptide Cancer Drugs: 143 Drugs
  • Peptide Cancer Therapeutics Market Future Growth Prospects

Table of Contents

1. Introduction to Peptide Cancer Therapeutics

2. Mechanism of Peptide Cancer Therapeutics

3. Peptide Cancer Therapeutics Market Outlook

  • 3.1 Market Overview
  • 3.2 Cancer Peptide Clinical Pipeline Overview

4. Peptide Cancer Therapeutics Market Dynamics

  • 4.1 Favorable Growth Parameters
  • 4.2 Key Issues to be Resolved

5. Peptide Cancer Therapeutics Market Future Growth Prospects

6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Clinical
  • 6.4 Phase-0
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-III

7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company

8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Market Withdrawal
  • 8.4 Suspended

9. Competitive Landscape

  • 9.1 AngioChem
  • 9.2 Antigen Express
  • 9.3 Amgen
  • 9.4 GlaxoSmithKline
  • 9.5 Galena Biopharma
  • 9.6 Ipsen
  • 9.7 Merck & Co
  • 9.8 PeptiDream
  • 9.9 Roche
  • 9.10 Sanofi
  • Figure 1-1: Use of Peptides in Various Ailments
  • Figure 2-1: Mode of Action of Peptide Cancer Therapeutics
  • Figure 2-2: Targeted Peptide Cancer Therapeutics Development
  • Figure 3-1: Global Peptide Market (US$ Billion), 2013-2018
  • Figure 3-2: Global Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-3: Global Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-4: No Development Reported in Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-5: No Development Reported in Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-6: Discontinued Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-7: Discontinued Peptide Cancer Drug Pipeline by Phase (Number), 2014
  • Figure 3-8: Suspended Peptide Cancer Drug Pipeline by Phase (%), 2014
  • Figure 3-9: Suspended Peptide Cancer Drug Pipeline by Phase (Number), 2014
Back to Top